7.78
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Scynexis Inc | SCYX | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 7.78 | 04:31:36 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.78 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
7.78 | 8.40 | 0.62 | - | - |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 50 | 703,031 | 0.50 - 10.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:21:26 | 50 | $ 7.79 | USD |
Scynexis Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 150.00M | 19.28M | 17.32M | $ 121.00k | $ - | -9.79 | -2.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Scynexis News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.66 | 9.01 | 7.41 | 8.16 | 613,381 | -0.88 | -10.16% |
1 Month | 7.43 | 10.15 | 7.26 | 8.72 | 674,540 | 0.35 | 4.71% |
3 Months | 6.55 | 10.15 | 5.82 | 7.88 | 681,789 | 1.23 | 18.78% |
6 Months | 5.65 | 10.15 | 4.2009 | 7.57 | 360,304 | 2.13 | 37.7% |
1 Year | 0.9364 | 10.15 | 0.50 | 3.10 | 551,870 | 6.84 | 730.84% |
3 Years | 1.65 | 10.15 | 0.35 | 1.78 | 620,363 | 6.13 | 371.52% |
5 Years | 4.85 | 10.15 | 0.35 | 2.05 | 509,908 | 2.93 | 60.41% |
Scynexis Description
SCYNEXIS Inc is drug development company which focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing lead product candidate, SCY-078 which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The SCY-078 is a novel and structurally distinct triterpenoid glucan synthase inhibitor which is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |